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ABSTRACT
The availability of an IV form of busulfan (Bu) has prompted investigation of administration schedules other than
the 4-times-daily dosage commonly used with oral Bu. We have studied an allogeneic stem cell transplantation
(SCT) preparative regimen comprising fludarabine (FLU) 50 mg/m2 on days –6 to –2 plus IV Bu 3.2 mg/kg daily in a
3-hour infusion on days –5 to –2. The regimen was given to 70 patients aged 15 to 64 years (median, 41 years) with
hematologic malignancy. Thirty-six patients (51%) had high-risk malignancy, 28 (40%) had unrelated or genotypi-
cally mismatched related donors (alternate donors [AD]) and 29 (41%) received bone marrow rather than blood as
stem cell source. Acute GVHD prevention comprised antithymocyte globulin 4.5 mg/kg over 3 days pretransplanta-
tion, cyclosporin A, and short-course methotrexate with folinic acid. Hepatic toxicity was transient and there was no
clinically diagnosed veno-occlusive disease. Grade II stomatitis occurred in 49 patients (70%) and hemorrhagic cys-
titis in 9 patients (13%). One patient with subtherapeutic phenytoin levels had a convulsion 8 hours after the third
IV Bu dose, but no other neurotoxicity was apparent. Incidence of acute GVHD grades II to IV was 8% and inci-
dence of grade III-IV was 3%, with no deaths from this cause. Actuarial incidence of chronic GVHD at 2 years is
38%. There were 2 cases of graft failure in unrelated donor BMT recipients, 1 of which was reversed by a second
transplantation. With a median follow-up of 16 months (range, 6-27 months), transplantation-related mortality at
100 days and 2 years was 2% and 5% for matched related donor (MRD) SCT and 8% and 19% for AD SCT, respec-
tively (P = not significant). Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete
remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and
18% for 17 patients with other active malignancy. Projected disease-free and overall survival rates at 2 years were
74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease,
respectively. Pharmacokinetic studies were done using 11 samples with the first and fourth doses of Bu. Kinetics
were linear, and for the first and fourth doses, the half-lives were 2.60 ± 0.44 and 2.57 ± 0.36 hours, respectively.
Clearances were 106.77 ± 16.68 and 106.86 ± 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 ± 0.31
and 3.96 ± 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 ±
771.42 and 4980 ± 882.80 µM × min, respectively. Bu was completely cleared within 24 hours and the day 4 pharma-
cokinetic values were very similar to those on day 1 for every patient. The cumulative AUC was comparable to the
target range established for PO Bu. This regimen incorporating once-daily IV Bu is convenient to give, is relatively
well tolerated, gives predictable blood levels, and deserves further study in circumstances in which cytoreduction as
well as immune suppression is needed.
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INTRODUCTION
Busulfan (Bu) is a frequent component of cytotoxic
preparative regimens for stem cell transplantation (SCT)
[1-7]. Until recently, Bu has been available only in an oral
form and has been given 4 times daily in the standard
BuCy2 (busulfan/cyclophosphamide) protocol. Not only
may patients vomit up oral Bu, but the unpredictable
bioavailability may lead to overdosing with a higher risk of
toxicity or to underdosing with graft failure or suboptimal
antitumor activity [6-25]. In addition, gut absorption of Bu
may contribute to veno-occlusive disease (VOD) of the liver
via a “ﬁrst pass” effect [26]. An intravenous (IV) preparation
(Busulfex; Orphan Medical, Minneapolis, MN) has been
recently developed and is currently the only such product
commercially available. It is hoped that the IV formulation
may avoid the inherent problems of oral administration and
improve the accuracy of dosing [27-29]. However, most
experience with IV formulations has been with the tradi-
tional 4-times-daily dosing [30,31]. If equally effective, daily
dosing of Bu would be more convenient, particularly in the
outpatient setting. Moreover, if the metabolic handling of
Bu is consistent with linear pharmacokinetics (PK) at higher
individual doses (>1 mg/kg), one would predict more unifor-
mity in exposure because there would be no accumulation
from one dose to the next.
Limited data indicate that daily oral doses seem to be
well tolerated in children [32]. There are also case reports of
inadvertent oral administration of single doses from 16 to
36 mg/kg, apparently without serious results apart from
seizures [33]. Finally, other IV preparations have been given
daily, albeit for only 2 days, and were well tolerated [34,35].
These data encouraged us to study the PK and clinical toxic-
ity profile of IV Bu given once daily in combination with
ﬂudarabine in a myeloablative conditioning protocol for allo-
geneic SCT (FLUdarabine BUsulfan Protocol [FLUBUP]).
PATIENTS AND METHODS
Patients
Clinical data are presented on 70 consecutive patients,
between May 1999 and January 2001, with hematologic
malignancy who received daily IV Bu. Some details of diag-
noses and stem cell sources are recorded in Table 1. For the
purpose of this analysis, low-risk patients were defined as
those with acute myeloid leukemia (AML) in ﬁrst complete
remission (CR1) or CR2 and those with chronic myeloid
leukemia (CML) in ﬁrst chronic phase; the remainder were
considered high-risk patients. Alternative donor (AD) trans-
plantations included recipients of SCT from unrelated and
genotypically mismatched family donors. All patients were
undergoing a ﬁrst SCT. The median follow-up of survivors
was 16 months (range, 6-27 months).
Treatment
Fludarabine 50 mg/m2 was given to all patients on days
–6 to –2. Patients received Bu (Busulfex; Orphan Medical) at
a dose of 3.2 mg/kg ideal body weight once daily IV as a
3-hour continuous infusion by pump through a right atrial
catheter. The infusion time was based on the regimen used
for a dimethyl sulfoxide–based Bu preparation by Jencke et al.
[34] (G. Ehninger, personal communication, 1999).
All patients received loading with oral or IV phenytoin
and continued dosing to maintain therapeutic levels of 40 to
80 µmol/L from days –5 through –2.
All patients were nursed without protective isolation [36].
All blood products were from cytomegalovirus seronegative
donors. Single donor platelets were given to maintain a
platelet count >10 × 109/L and red cells to keep the hemoglo-
bin level >80 g/L. Growth factors were not given routinely.
Antibacterial and antipneumocystis prophylaxis comprised
ciprofloxacin 500 mg twice a day and trimethoprim/sulfa-
methoxazole twice weekly; no systemic antifungal prophylaxis
was used. The acute graft-versus-host disease (GVHD) pro-
phylaxis protocol comprised cyclosporin A orally or intra-
venously twice daily to maintain blood levels between 150 and
400 µmol/L. Methotrexate was given in doses of 15 mg/m2 on
day 1 and 10 mg/m2 on days 3, 6, and 11. Folinic acid 5 mg
was started 24 hours after each dose of methotrexate and con-
tinued every 6 hours until 12 hours before the next dose [37].
Rabbit antithymocyte globulin (ATG) (Thymoglobulin; Sang-
stat, Fremont, CA) 4.5 mg/kg was given in divided doses of
0.5, 2, and 2 mg/kg on days –2, –1, and 0, respectively.
Engraftment
Daily blood counts were taken until hospital discharge,
with bone marrow aspirations at 3 months for surviving
Table 1. Patient Characteristics*
Number 70
Age, y, median (range) 41 (15-64)
Diagnosis
Low risk (n = 34)
CML in first chronic phase 14
AML CR1 17
AML CR2 3
High risk (n = 36)
CML in accelerated phase 2
MDS (RARS) 1
CLL: Refractory CLL (4) /prolymphocytic 8 
leukemia (1) /Richter’s (3)
Advanced AML (9)† and/or AML arising from MDS 19
Relapsed/refractory HD 1







Genotypically matched related 43
Mismatched related‡ 6
Unrelated (serological match A and B, molecular 21 
match DRB1 and DQB1)
*MDS indicates myelodysplastic syndrome; RARS, refractory ane-
mia with ringed sideroblasts; CLL, chronic lymphocytic leukemia; HD,
Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; DLCL, diffuse
large cell lymphoma.
†Four primary refractory, 5 ﬁrst relapse (1 refractory, 1 pancyto-
penic after further chemotherapy).
‡Two phenotypically identical (1 parent, 1 child), 2 A mismatch
(1 sibling, 1 parent), 1 B and C mismatched sibling, 1 B and 2 C mis-
matched sibling.
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patients or as clinically indicated. Granulocyte engraftment
was deﬁned as a count of >0.5 × 109/L. The platelet count
needed to be above 20 × 109/L without transfusion for 3 days.
If neither level had been reached by day 28, in the absence
of persistent malignancy in the bone marrow, the patient
was deemed to have primary graft failure.
The source of engrafted cells in peripheral blood and/or
bone marrow was confirmed by comparison of donor and
recipient polymerase chain reaction (PCR) amplified and
radiolabeled DNA fragments resolved on polyacrylamide
gels and detected by autoradiography [38].
Toxicity Evaluation
Stomatitis was evaluated according to the Bearman scale
with grade I not requiring analgesia and grade II needing
continuous systemic analgesics [39]. Hemorrhagic cystitis was
deﬁned as macroscopic hematuria accompanied by pain on
voiding. Hepatotoxicity was determined according to liver
function tests performed before transplantation and twice
weekly posttransplantation. The maximum alanine amino-
transferase (ALT) and conjugated bilirubin levels before and
in each of the ﬁrst 4 weeks after SCT were recorded, and the
median values for each patient group were plotted. VOD was
diagnosed according to previously described criteria [40].
PK Studies
Twelve patients, 4 in each risk group, had blood sam-
pling for PK studies. Blood samples (5 mL) were taken
before Bu infusion and then at target time points of 1, 1.5,
2.9, 3.25, 3.5, 4, 6, 8, 10, 12, 16, and 24 hours after the start of
the infusion. Sampling was done with the ﬁrst and fourth doses
only. Samples were taken from a peripheral vein into pre-
chilled heparin tubes with plasma separation within 30 min-
utes. Plasma was separated by centrifugation at 2500 rpm for
10 minutes at 4°C within 1 hour, placed in cryogenic vials,
and stored at –40°C until analyzed by a validated high-pressure
chromatography as previously described [30,41-43].
The Bu peak concentrations (Cmax) are observed values.
Parameters such as volume of distribution and elimination
rate constant were estimated, whereas half-lives and clear-
ance were calculated from the primary parameters. The Bu
area under the plasma concentration versus time curve
(AUC) per Bu dose was calculated by dividing the drug dose
by the Bu plasma clearance estimate. The fourth-dose Bu
plasma clearance was determined by modeling Bu plasma
concentration versus time data from dose 1 and dose 4. The
PK modeling was performed using ADAPT II Software Ver-
sion 4.0 (BMRS, University of Southern California, Los
Angeles, CA) [44].
Informed Consent
All recipients of FLUBUP were fully informed about
the investigational nature of the regimen, and the purpose
of the PK studies was explained to selected patients. The
protocol and consent forms were approved by the Univer-
sity of Calgary Conjoint Medical Ethics Committee. All
patients gave written consent.
Statistical Analysis
The distributions of time to events were analyzed using
the log-rank test, with patients being censored for relapse
for estimation of nonrelapse mortality. The distributions of
time to events were compared using the log-rank test. P val-
ues were reported only if 0.1 or less; those between 0.05 and
0.1 are referred to in the text as trends. Analysis was per-
formed on a Macintosh computer using GraphPad Prism
software (GraphPad, San Diego, CA).
RESULTS
Engraftment
Of patients alive at day 28, 2 had failed engraftment
because of persistent leukemia. For unrelated donor trans-
plants, the median nucleated cell dose was 2.44 × 108/kg
(range, 0.29-10.62 × 108/kg) and the median CD34+ cell
dose was 2.88 × 106/kg (range, 0.78-18.32 × 108/kg). Two
unrelated donor BMT recipients with CML had primary
graft failure after nucleated cell doses of 2.4 × 108/kg and
0.83 × 108/kg and CD34+ cell doses of 3.87 × 106/kg and
3.44 × 106/kg, respectively. Both received a second infusion
after conditioning with fludarabine 50 mg/m2 for 5 days,
total body irradiation (TBI) 200 cGy ×2 fractions, and
ATG 4.5 mg/kg over 3 days. One patient had successful
engraftment, and the other died of infection before
engrafting.
Among the remaining patients, neutrophil engraftment
occurred at a median of 18 days (range, 12-42 days) and
platelet engraftment at 19 days (range, 0-36 days).
Regimen-Related Toxicity
Neurotoxicity. One patient had a convulsion after the third
dose of Bu. The phenytoin level at the time was 16.6 µmol/L
(therapeutic range, 40-80 µmol/L). There was no other evi-
dence of neurotoxicity attributable to Bu.
Stomatitis and Hemorrhagic Cystitis. Grade II stomatitis
occurred in 49 patients (70%) and hemorrhagic cystitis in 9
(13%). The cystitis was invariably self-limiting with no
long-term sequelae.
Hepatotoxicity. There was some histological evidence of
VOD at autopsy in a patient who died suddenly on day 19,
but liver function was improving at the time of death and
she did not satisfy clinical criteria for VOD. Transient eleva-
tion of ALT to above normal levels occurred in 52 patients
(74%), with levels usually peaking during the first week
(Figure 1A). Conjugated bilirubin levels became elevated in
62 patients (89%), with peak levels tending to occur in the
second week after SCT (Figure 1B).
Graft-versus-Host Disease. The actuarial incidence rate of
acute GVHD grades II to IV was 9% ± 4% and for grades
III to IV disease was 3% ± 2%, with no difference between
MRD and AD (grades II-IV, 10% ± 5% versus 9% ± 6%;
grades III-IV, 3% ± 3% versus 5% ± 4%) (Figure 2A). At
2 years, the projected incidence rate of chronic GVHD was
38% ± 7%, with no difference between MRD and AD at
41% ± 9% and 31% ± 11%, respectively (Figure 2B). No
deaths were primarily attributable to either acute or chronic
GVHD.
Relapse
By 2 years, the projected relapse rates were 21% ± 8%
in low-risk patients, 66% ± 12% in high-risk AML patients,
and 18% ± 9% for other high-risk patients (Figure 2C).
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Transplantation-Related Mortality
One patient with a prior history of cardiac failure died
on day 8 after a myocardial infarction. A second patient,
referred to above, died suddenly on day 19; the cause was
not apparent at autopsy. The third early death, on day 73,
was in the CML patient with graft failure. Three late deaths
have occurred, 1 on day 129 from cytomegalovirus, 1 on day
163 from a pulmonary embolus, and the third on day 182
after a second mismatched BCT for late graft failure. Over-
all actuarial nonrelapse mortality rate at 100 days was 5% ±
3% (MRD, 2% ± 2%; AD, 8% ± 6%, P = not signiﬁcant)
and at 2 years was 10% ± 4% (MRD, 5% ± 4%; AD, 19% ±
9%, P = not signiﬁcant) (Figure 2D).
Disease-Free and Overall Survival
With a median follow-up of 16 months (range, 6-
27 months), the projected 2-year relapse-free survival rate
was 74% ± 8% for low-risk patients, 26% ± 11% for high-
risk AML patients, and 65% ± 12% for the other high-risk
patients (Figure 3A). Projected overall survival rates at 1 and
2 years for the 3 groups were 88% ± 6%, 37% ± 11%, and
71% ± 11% respectively (Figure 3B). There is no signiﬁcant
difference in these respects between recipients of MRD or
AD SCT.
PK Studies
Details of the PK results in 12 patients are given in
Table 2. For each patient, the PK parameters did not change
significantly between the first and fourth dose. For the
group, the mean dose of IV Bu was 2.91 mg/kg (based on
actual body weight), which resulted in an estimated AUC of
4867 µM × min and 4980 µM × min for the ﬁrst and fourth
dose, respectively. With this once-daily dosing of IV Bu, Bu
was completely cleared within 24 hours and the day 4 PK
Figure 1. A, Pattern of ALT (U/L). Horizontal dotted line shows upper limit of normal range. B, Pattern of conjugated bilirubin (µmol/L). Hori-
zontal dotted line shows upper limit of normal range.
A
B
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plots were very similar to those on day 1 for every patient
analyzed (Figure 4).
The only patient dying without relapse was the individ-
ual referred to above who died suddenly on day 19, patient
13 in Table 2. Bu AUC was in the middle of the measured
range, at about 5000 µM × min.
DISCUSSION
The combination of oral Bu with various doses of
cyclophosphamide (Cy) is currently the most widely used
myeloablative regimen not incorporating TBI. Randomized
comparisons of BuCy2 (16 mg/kg Bu and 120 mg/kg Cy)
with Cy and TBI (1200 cGy) have generally indicated com-
parable efficacy in myeloid leukemias [3-7]. Given our
understanding of the difficulty patients have keeping the
pills down plus the often erratic and unpredictable absorp-
tion, the combination of oral Bu with Cy could be seen as
surprisingly successful. Doubtless some of the shortcomings
of these regimens can be attributed either to inadequate
exposure, with leukemic relapse and/or graft failure, or to
toxic levels and consequent organ damage, particularly
VOD [8,18-21,23-26,30,31]. An IV preparation has the
potential of delivering optimum doses and allowing further
evaluation of the therapeutic potential of Bu.
The early BuCy regimens required Bu to be given
4 times daily, at least in part because of the difﬁculty some
patients would have with less frequent dosing. The initial
studies with IV Bu used the same dosing intervals and have
demonstrated predictable and consistent PK profiles with
acceptable toxicity [30]. Single daily dosing would be much
more convenient and would be expected to be equally effec-
tive if comparable exposure, reflected in AUC, could be
achieved with acceptable toxicity.
Our decision to use IV Bu with Flu was based on pre-
liminary studies indicating that the FLUBUP combination
using oral Bu was at least as well tolerated as BuCy2 [45].
We have found little difference in toxicity between the oral
and IV preparations but have moved exclusively to the IV
form because of the more predictable PK [46].
The current study indicates that the combination of Flu
with daily IV Bu is very well tolerated. Failure to engraft
was seen only in AD transplants, and currently such failures
seem no more frequent than with other regimens. This
study cannot evaluate speed of engraftment in comparison
with other combinations because of the inﬂuence of disease
stage, donor, and cell source. Stomatitis is the most pre-
dictable toxicity but is self-limiting and less frequent with
IV Bu than with oral BU in our experience [46]. Cystitis
occurs with IV Bu at a similar frequency to that with
BuCy2, perhaps partly explaining the lack of success when
prophylactic measures are simply directed at Cy [45]. The
mechanism by which Bu contributes to cystitis is uncertain,
but fortunately this complication is generally brief and self-
limiting. Hepatotoxicity seems generally mild and transient;
the single case of histologic VOD observed at autopsy was
not presenting a clinical problem at the time of death. The
pattern of liver function abnormalities resembles that seen
after BuCy2 and oral Bu with Flu [45,46]. The similar toxic-
ity proﬁles of the current regimen, BuCy2, and oral Bu with
Flu may indicate that daily IV Bu combined with Cy would
be equally tolerable.
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Both Bu and Flu are known to penetrate the central ner-
vous system and have been responsible for neurotoxicity,
usually convulsions in the case of Bu. Neurological side
effects have also been attributed to dimethylacetamide, used
with PEG-400 in the solvent system for IV Bu [27-29,47].
We observed only 1 neurological event, a generalized seizure
in a patient whose phenytoin level was subtherapeutic.
Our patients were mostly adults, about half with high-
risk disease and one third with donors other than matched
siblings. Transplantation-related mortality at 100 days is
commonly taken as an indicator of the acute toxicity of the
transplantation procedure, and the rates in this study of 8%
for AD and 2% for MRD are relatively low. An overall non-
relapse mortality rate of about 10% at this report also indi-
cates that this regimen seems to result in no major delayed
effects. There was no predominant cause of death, with
none attributable to GVHD. Although the addition of ATG
to a methotrexate and cyclosporin regimen may account for
the low morbidity and mortality from GVHD, it may also
make evaluating the antileukemic potential of the IV Bu dif-
ficult. The contribution of a graft-versus-leukemia effect
could be relatively weak in the majority of patients without
signiﬁcant GVHD. The observation by Andersson et al. that
GVHD may be affected by the intensity of the conditioning
regimen may also be relevant [31]. The more predictable
behavior of Bu when given IV could result in less severe
GVHD if toxic levels are avoided. The relative contribu-
tions of these effects cannot be determined in a study such
as ours. Nevertheless, there is no indication from our data of
higher-than-expected relapse rates in advanced malignancy.
The striking differences in relapse for high-risk AML compared
with other diagnoses indicate that it may be inappropriate to
consider all high-risk patients as a single group in studies such
as this and highlight the need for additional disease-specific
evaluation of this regimen.
The PK studies indicate that daily IV Bu gives pre-
dictable linear kinetics, with less variability than reported
with oral dosing. The day 1 and day 4 curves are very simi-
lar, and there is no accumulation from one dose to the next.
The half-life of about 2.5 hours is somewhat shorter than
the median of 3.8 hours reported by Phadungpojna et al.
for IV Bu given 4 times daily in a large phase II study [29].
A B
Figure 3. A, Disease-free survival. B, Survival.
Table 2. PK Parameters of Once-Daily IV Bu*
IV Bu IV Bu Dose 1 Dose 4
Patient Dose, Dose, Cmax, Clearance, Clearance, AUC, Cmax, Clearance, Clearance, AUC,
ID mg/M2 mg/kg mcg/mL T1/2, h mL/min/M
2 mL/min/kg µM × min mcg/mL T1/2, h mL/min/M
2 mL/min/kg µM × min
1 133.33 2.71 3.94 2.58 102.70 2.09 5277.38 4.03 2.72 98.68 2.01 5492.36
2 127.27 2.96 3.62 2.31 130.23 3.03 3972.69 3.97 2.09 124.27 2.89 4163.32
3 131.82 3.16 3.92 2.55 113.26 2.71 4731.07 3.58 2.55 124.42 2.98 4306.71
4 117.35 3.11 4.29 2.67 81.88 2.17 5825.79 4.25 2.94 80.07 2.12 5957.48
9 123.76 3.11 3.64 2.20 112.75 2.83 4462.03 3.60 2.31 107.73 2.71 4669.95
11 132.30 2.76 3.80 3.04 105.60 2.20 5092.63 4.60 2.75 106.40 2.22 5054.34
13 126.37 2.78 4.30 2.48 99.85 2.19 5144.81 4.50 2.59 105.93 2.33 4849.51
15 128.57 2.57 4.00 2.57 103.50 2.07 5049.69 3.75 2.58 114.13 2.28 4579.36
17 123.08 3.24 4.20 3.49 80.12 2.11 6244.48 4.50 3.29 76.03 2.00 6580.40
19 116.82 2.69 4.20 2.96 97.00 2.23 4895.70 3.90 3.00 94.38 2.17 5031.61
20 126.37 3.00 3.80 2.57 120.30 2.86 4270.23 3.80 2.53 115.10 2.73 4463.15
21 113.21 2.90 3.30 1.74 134.10 3.43 3431.68 3.10 1.74 141.10 3.61 3261.44
Mean 125.02 2.91 3.92 2.60 106.77 2.49 4866.51 3.96 2.57 106.86 2.50 4979.97
SD 6.47 0.21 0.31 0.44 16.68 0.46 771.42 0.28 0.36 21.57 0.51 882.85
*T1/2 indicates half-life.
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The AUCs achieved in our 12 test subjects were scattered
around the range deemed optimal from studies with oral
Bu. Thus, the target recommended by Phadungpojna et al.
for Bu given 4 times a day was 1100 to 1200 µM × min per
dose [29]. This amount would be equivalent to 4400 to
4800 µM × min per day, close to our mean level of 4900 to
5000 µM × min and well below the cumulative AUC over
4 days of 6000 µM × min reported to be associated with an
increased risk of VOD [20]. The AUC for 1 patient
exceeded this limit and in another patient the AUC was
between 3000 and 4000 µM × min, possibly suboptimal
exposure. Given readily available Bu levels, it may now be
possible to target precise AUC values after either a test
dose or the first therapeutic dose. It remains to be deter-
mined whether this ability will demonstrably improve out-
comes compared with dosing by weight alone. It is also
unclear whether similar targets are desirable for IV com-
pared with oral Bu.
IV Bu offers the possibility of ensuring drug exposures
that are antileukemic and allow engraftment without undue
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toxicity. If further studies conﬁrm our initial impressions, we
predict a trend toward daily dosing and perhaps even fewer
and higher doses. It may then be appropriate to compare
conditioning regimens containing Bu administered in a con-
sistent fashion with those incorporating TBI.
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